These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12040346)

  • 1. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial.
    Berger PB; Mahaffey KW; Meier SJ; Buller CE; Batchelor W; Fry ET; Zidar JP;
    Am Heart J; 2002 May; 143(5):841-6. PubMed ID: 12040346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparin in coronary stenting.
    Zidar JP
    Can J Cardiol; 1998 Aug; 14 Suppl E():35E-39E. PubMed ID: 9779032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
    Berger PB; Bell MR; Hasdai D; Grill DE; Melby S; Holmes DR
    Circulation; 1999 Jan; 99(2):248-53. PubMed ID: 9892591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
    Batchelor WB; Mahaffey KW; Berger PB; Deutsch E; Meier S; Hasselblad V; Fry ET; Teirstein PS; Ross AM; Binanay CA; Zidar JP;
    J Am Coll Cardiol; 2001 Nov; 38(6):1608-13. PubMed ID: 11704394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
    Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    Mauri L; Kereiakes DJ; Yeh RW; Driscoll-Shempp P; Cutlip DE; Steg PG; Normand SL; Braunwald E; Wiviott SD; Cohen DJ; Holmes DR; Krucoff MW; Hermiller J; Dauerman HL; Simon DI; Kandzari DE; Garratt KN; Lee DP; Pow TK; Ver Lee P; Rinaldi MJ; Massaro JM;
    N Engl J Med; 2014 Dec; 371(23):2155-66. PubMed ID: 25399658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subacute thrombosis with antiplatelet treatment in a non-selected population of intracoronary stents: incidence and predictors].
    Pascual Figal DA; Valdés Chávarri M; Ruipérez JA; Cortés R; López Pálop R; Picó Aracil F; García Alberola A
    Rev Esp Cardiol; 2000 Jun; 53(6):791-6. PubMed ID: 10944971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
    Lee SW; Park SW; Hong MK; Kim YH; Lee BK; Song JM; Han KH; Lee CW; Kang DH; Song JK; Kim JJ; Park SJ
    J Am Coll Cardiol; 2005 Nov; 46(10):1833-7. PubMed ID: 16286167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for low-molecular weight heparin in coronary stenting.
    Zidar JP
    Am Heart J; 1997 Nov; 134(5 Pt 2):S81-7. PubMed ID: 9396639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
    Bartorelli AL; Tamburino C; Trabattoni D; Galassi A; Serdoz R; Sheiban I; Piovaccari G; Zimarino M; Benassi A; Di Mario C; Sangiorgio P; Chierchia S; Reimers B;
    Am J Cardiol; 2007 Apr; 99(8):1062-6. PubMed ID: 17437728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry.
    Orford JL; Lennon R; Melby S; Fasseas P; Bell MR; Rihal CS; Holmes DR; Berger PB
    J Am Coll Cardiol; 2002 Nov; 40(9):1567-72. PubMed ID: 12427407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
    Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
    Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cilostazol versus ticlopidine therapy after stent implantation.
    Park SW; Lee CW; Kim HS; Lee HJ; Park HK; Hong MK; Kim JJ; Park SJ
    Am J Cardiol; 1999 Sep; 84(5):511-4. PubMed ID: 10482146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive therapies in the cath lab. Subacute stent thrombosis developing twelve days after discontinuation of ticlopidine treatment.
    Timurkaynak T; Goksen I; Cengel A; Dortlemez O
    J Invasive Cardiol; 2001 Sep; 13(9):640-3. PubMed ID: 11533502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).
    Urban P; Macaya C; Rupprecht HJ; Kiemeneij F; Emanuelsson H; Fontanelli A; Pieper M; Wesseling T; Sagnard L
    Circulation; 1998 Nov; 98(20):2126-32. PubMed ID: 9815866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
    Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
    JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.